BNET Industries
Market Cap:$332.1M
Last Fiscal Year Sales:$42.3M
- Public
Dow Jones Description
Otish Resources, Inc. is a Delaware corporation formed in February, 2003. Otish Resources, Inc. is a mineral exploration stage company. The Company has specialized in acquiring and consolidating mineral properties with potential to have commercial ore bodies. Our property acquisition emphasis has focused on properties with diamonds and other strategic minerals that are located in Quebec, Canada. Since the Company is an exploration stage company there is no assurance that a commercially viable mineral deposit exists on any properties which it currently owns. Further, exploration will be required before a final evaluation as to the economic and legal feasibility is determined. The Company initially acquired three properties located in NTS Areas 33A02 (Lac Lavallette), 23D04 (Lac Laparre) and 33A01 (Lac Barou) of the Otish Mountains diamond exploration area in Baie James Region in Northern Quebec. The claims were staked by Mr. Lee Barker , MSc. PEng., PGeol., based on an interpretation of reprocessed Canadian government aeromagnetic survey data. All claim groups require further exploration to assess their potential to host discrete intrusives that could be similar to the diamondiferous kimberlite bodies recently discovered in the region.
President
Crocker CoulsonNumber of Employees 360
Contact Information
999 Ningqiao Road Jinqiao Export Processing Zone
Shanghai 201206
(86) 21 58349748
Peer Companies
NAICS Code Food (Health) Supplement Stores: 446191
Recent Events
-
Build Your Fortune With These Winners
-
China-Biotics Slips To Q2 Loss - Update
-
China-Biotics, Inc. Reports FY10 Q2 Results
-
China-Biotics Inc elects Dr. Tom Gu as vice president
-
China-Biotics Reports Resignation Of Lewis Fan As CFO - Quick Facts
-
China-Biotics CFO resigns to purse other interests
-
China-Biotics raises $69 million in public offering of common stock
-
Todays Zacks Rank Momentum Buy: China Biotics Inc.
News & Analysis
Filter by
china-biotics inc. - All News and Analysis
China-Biotics: An Undervalued Stock with a Growth Catalyst
Seeking Alpha
- 2009-08-26
China-Biotics Inc. CHBT may not be in the most glamorous business dealing with bacteria, but its stock appears quite appetizing for investors. The company is one of the few domestic producers of probiotics in a baby formula market that primarily relies on imports, while it is also rapidly expanding its...
China-Biotics Reports Gains in FY2009
Seeking Alpha
- 2009-07-15
ChinaBio Today submits: China-Biotics, Inc. (NSDQ: CHBT) reported positive financial results for its 2009 fiscal year, which ended in March. Sales rose 28% to $54.2 million, and non-GAAP net income climbed 19% to $16.9 million, a very healthy margin of 31%. Revenues were in line with analysts’ expectations, but...
China-Biotics's Q3 Shows Improvement
Seeking Alpha
- 2009-02-17
ChinaBio Today submits: China-Biotics, Inc. CHBT released its Q3 financial report, showing that, compared to last’s years Q3, revenues climbed 33% to $15.8 million while net income rose 40% to $5.7 million. The company, which makes probiotic products, attributed its improved performance to a combination of new products and...
Four Probiotic Products Added to China-Biotics' Lineup
Seeking Alpha
- 2009-01-21
ChinaBio Today submits: China-Biotics, Inc. (NSDQ: CHBT) received manufacturing certificates from the SFDA for several additions to its probiotic line of products. These include Synbiotics Capsules, Probiotics Gegen Capsules, Probiotics Tremella Polysaccharide Capsules and Probiotics Chewable Tablets. Probiotics are live microbial food supplements designed to promote intestinal microbial balance....
China-Biotics Delays Plant Construction on Regulatory Conflicts
Seeking Alpha
- 2009-01-14
ChinaBio Today submits: China-Biotics, Inc. CHBT, a probiotics company, reported that construction of its new manufacturing plant in Shanghai has been delayed. The company blamed the delay on regulatory conflicts. Two agencies have jurisdiction over the facility, the SFDA and the Shanghai Municipal Bureau of Quality and Technical Supervision,...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Crocker Coulson | President |
| Lewis Fan | CFO |
| Raymond Li | Chief Financial Officer |
| Yihong Yan | Chief Administrative Officer MS |
| Weida Huang |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Chin Ji Wei | Board of Directors |
| Du Wen Min | Board of Directors |
| Ji Wei Chin | Board of Directors |
| Simon Yick | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | President | Current |
Mr. Fan has served as Chief Financial Officer since 2009. Prior to joining China-Biotics, Mr. Fan was Vice President and Senior Equity Analyst for Brean Murray, Carret & Co., where he covered the Chinese healthcare industry. He previously served as an equity analyst at UBS and as an emerging markets strategist at Deutsche Bank. Prior to his Wall Street career, Mr. Fan served as a research scientist focusing on natural product drug discovery at Schering-Plough. He holds a Master of Business Administration degree in finance from New York University, a Master of Science degree in medicinal chemistry from the University of Michigan and a Bachelor of Arts degree with honors in biology and chemistry from Luther College.
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | CFO | Current |
Array
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Chief Financial Officer | Current |
Yihong Yan, Chief Administrative Officer Ms. Yan is the CAO (assistant to the general manager) of China-Biotics. She has served as a director since 1999. She was appointed CAO in 2004, and her term will expire in 2008. During the past five years, Ms. Yan has participated in formulating the Company's development plans, implemented internal control procedures and represented the Company in business negotiations with relevant government authorities and other external parties.
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Chief Administrative Officer MS | Current |
Weida Huang, Technical Advisor Dr. Huang co-founded Shining and is a member of the Company's technical advisory panel responsible for product development and applications. Since 1990, he has taught at Fudan University's School of Life Science as an instructor for doctoral students. Dr. Huang is renowned for his studies and research in life science; his research work has earned him a number of research and development awards.
| Organization | Position | Status |
|---|---|---|
| Shining Ltd. | Founder | Current |
| China-Biotics, Inc | Current |
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Board of Directors | Current |
Dr. Du has served in this role since January 2007. He has served as the Deputy Director in charge of the Centre for Adverse Drug Reactions in Shanghai since 2001. Dr. Du has also served as the Vice Chairman of Evaluation of Pharmacology & Clinical Pharmacy in Shanghai and the Vice Chairman at the Centre for the Study of Liver Disease in Shanghai since 2006.
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Board of Directors | Current |
Dr. Ji Wei Chin, Independent Director a " Dr. Chin has served in this role since January 2007. Dr. Chin has more than 20 years of academic experience as a lecturer and researcher in the field of horticulture.
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Board of Directors | Current |
Mr. Yick has served in this role since January 2007. He has more than 20 years of experience in corporate finance, direct investment and auditing.
| Organization | Position | Status |
|---|---|---|
| China-Biotics, Inc | Board of Directors | Current |
Executive News
-
China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
-
China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
| Volume | 161,931 |
| Shares Outstanding | 22.3M |
| Market Cap | 332.1M |
| Year High | 19.00 |
| Year Low | 5.42 |
| Earnings Per Share | 0.75 |
| P/E Ratio | 19.80 |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
H. J. Heinz Company F2Q10 (Qtr End 10/28/09) Earnings Call Transcript
on Nov 24, 2009about HNZ
-
Hormel Foods Corporation F4Q09 (Qtr End 25/10/09) Earnings Call Transcript
on Nov 24, 2009about HRL
-
Campbell Soup Company F1Q10 (Qtr End 11/01/09) Earnings Call Transcript
on Nov 23, 2009about CPB
-
Tyson Foods, Inc. F4Q09 (Qtr End 10/03/09) Earnings Call Transcript
on Nov 23, 2009about TSN
-
The J.M. Smucker Company F2Q10 (Qtr End 10/31/09) Earnings Call Transcript
on Nov 20, 2009about SJM
Glass Door
Food Industry Companies
| Company | Employer Rating |
| Kraft Foods |  |
| ADM |  |
| Kellogg |  |
| Heinz | |
| General Mills |  |
IndustryTop Rated
